Acetyl-Histone H3 (Lys9)抗体;Acetyl-Histone H3 (Lys9) Antibody—艾普蒂 新品

+ +

•  

   

     Western blot analysis of Acetyl-Histone H3 (Lys9) in COS7 and C6 lysates using Acetyl-Histone H3 (Lys9) antibody.    

  
  

Acetyl-Histone H3 (Lys9) antibodies are essential tools for studying epigenetic regulation, specifically targeting histone H3 acetylated at lysine 9 (H3K9ac). Histone acetylation is a dynamic post-translational modification that modulates chromatin structure and gene expression. Acetylation of lysine residues, such as K9 on histone H3. neutralizes their positive charge, reducing interaction with negatively charged DNA. This loosens chromatin compaction, enabling transcription factors and RNA polymerase to access DNA, thereby promoting transcriptional activation. H3K9ac is strongly associated with active promoters and enhancers, serving as a hallmark of open, transcriptionally active chromatin regions.

These antibodies are widely used in techniques like chromatin immunoprecipitation (ChIP), Western blotting, and immunofluorescence to map acetylation patterns and investigate their role in gene regulation. Studies leveraging Acetyl-Histone H3 (Lys9) antibodies have linked H3K9ac to processes such as cell differentiation, DNA repair, and stress responses. Dysregulation of H3K9ac has been implicated in diseases, including cancers, neurological disorders, and metabolic syndromes, often correlating with aberrant gene expression due to disrupted histone acetyltransferase (HAT) or deacetylase (HDAC) activity. Researchers also use these antibodies to evaluate the efficacy of HDAC inhibitors in restoring normal acetylation levels during therapeutic interventions. Specificity validation via knockout controls or peptide competition assays is critical, as cross-reactivity with other acetylated histone residues may occur. Overall, these antibodies provide critical insights into chromatin dynamics and epigenetic mechanisms underlying health and disease.